CN112138113A - Compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and preparation method thereof - Google Patents
Compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and preparation method thereof Download PDFInfo
- Publication number
- CN112138113A CN112138113A CN202011169664.2A CN202011169664A CN112138113A CN 112138113 A CN112138113 A CN 112138113A CN 202011169664 A CN202011169664 A CN 202011169664A CN 112138113 A CN112138113 A CN 112138113A
- Authority
- CN
- China
- Prior art keywords
- treating
- cryptococcus neoformans
- ethanol
- killing
- cryptococcus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007336 Cryptococcosis Diseases 0.000 title claims abstract description 45
- 241000221204 Cryptococcus neoformans Species 0.000 title claims abstract description 42
- 239000002775 capsule Substances 0.000 title claims abstract description 23
- 241000411851 herbal medicine Species 0.000 title claims abstract description 14
- 150000001875 compounds Chemical class 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 44
- 244000178320 Vaccaria pyramidata Species 0.000 claims abstract description 12
- 235000010587 Vaccaria pyramidata Nutrition 0.000 claims abstract description 12
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 11
- JHGWQSGWUPCKNT-UHFFFAOYSA-N 2-tert-butyl-4-methyl-1,3,5-trinitrobenzene Chemical compound CC1=C([N+]([O-])=O)C=C([N+]([O-])=O)C(C(C)(C)C)=C1[N+]([O-])=O JHGWQSGWUPCKNT-UHFFFAOYSA-N 0.000 claims abstract description 10
- 241000903946 Clematidis Species 0.000 claims abstract description 7
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 40
- 239000000843 powder Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 9
- 239000011265 semifinished product Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 241000402754 Erythranthe moschata Species 0.000 claims description 3
- 238000011049 filling Methods 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 15
- 206010035664 Pneumonia Diseases 0.000 abstract description 10
- 201000009906 Meningitis Diseases 0.000 abstract description 9
- 206010037660 Pyrexia Diseases 0.000 abstract description 9
- 206010014599 encephalitis Diseases 0.000 abstract description 8
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000008673 vomiting Effects 0.000 abstract description 7
- 201000010099 disease Diseases 0.000 abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 206010036790 Productive cough Diseases 0.000 abstract description 5
- 206010042674 Swelling Diseases 0.000 abstract description 5
- 230000008961 swelling Effects 0.000 abstract description 5
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004400 mucous membrane Anatomy 0.000 abstract description 4
- 208000024794 sputum Diseases 0.000 abstract description 4
- 210000003802 sputum Anatomy 0.000 abstract description 4
- 241000233866 Fungi Species 0.000 abstract description 3
- 208000037976 chronic inflammation Diseases 0.000 abstract description 3
- 210000004916 vomit Anatomy 0.000 abstract description 3
- 230000006020 chronic inflammation Effects 0.000 abstract description 2
- 230000035876 healing Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 32
- 208000024891 symptom Diseases 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- 208000002173 dizziness Diseases 0.000 description 15
- 206010019233 Headaches Diseases 0.000 description 12
- 206010047700 Vomiting Diseases 0.000 description 11
- 231100000869 headache Toxicity 0.000 description 11
- 230000000843 anti-fungal effect Effects 0.000 description 8
- 229940121375 antifungal agent Drugs 0.000 description 8
- 238000001514 detection method Methods 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 208000002193 Pain Diseases 0.000 description 6
- 239000000796 flavoring agent Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 208000030507 AIDS Diseases 0.000 description 5
- 206010008479 Chest Pain Diseases 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 208000008454 Hyperhidrosis Diseases 0.000 description 5
- 208000006083 Hypokinesia Diseases 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 229940126673 western medicines Drugs 0.000 description 5
- MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 241000931143 Gleditsia sinensis Species 0.000 description 4
- 241000219784 Sophora Species 0.000 description 4
- 241001671204 Stemona Species 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 241000218158 Clematis Species 0.000 description 3
- 241000218202 Coptis Species 0.000 description 3
- 235000002991 Coptis groenlandica Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010028813 Nausea Diseases 0.000 description 3
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000037315 hyperhidrosis Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 230000008693 nausea Effects 0.000 description 3
- 239000002023 wood Substances 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 206010007882 Cellulitis Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000024753 bloody sputum Diseases 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 2
- 229960004884 fluconazole Drugs 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 244000045947 parasite Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 229930183010 Amphotericin Natural products 0.000 description 1
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 241000099774 Cuscuta salina Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 206010060710 Galactostasis Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 241000029132 Paronychia Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 241000517306 Pediculus humanus corporis Species 0.000 description 1
- 201000005702 Pertussis Diseases 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 208000007074 Trichomonas Vaginitis Diseases 0.000 description 1
- 208000025206 Trichomonas vaginitis urogenital infection Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 208000020560 abdominal swelling Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 229940009444 amphotericin Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 208000026500 emaciation Diseases 0.000 description 1
- XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 1
- 229960004413 flucytosine Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 244000000008 fungal human pathogen Species 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000000147 hypnotic effect Effects 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 208000026425 severe pneumonia Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/489—Sophora, e.g. necklacepod or mamani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/483—Gleditsia (locust)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/716—Clematis (leather flower)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/904—Stemonaceae (Stemona family), e.g. croomia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Communicable Diseases (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and a preparation method thereof are disclosed, wherein the mixture ratio is as follows: 15-30 g of radix sophorae flavescentis, 15-20 g of radix stemonae, 20-25 g of radix clematidis, 15-25 g of honeysuckle, 10-15 g of spina gleditsiae, 15-20 g of coptis chinensis, 20-25 g of cowherb seed and 5-10 g of artificial musk. The invention can effectively kill the fungi which cause meningitis, encephalitis, pneumonia, skin and mucous membrane infection caused by cryptococcus neoformans, can treat chronic inflammation, thick swelling, cough, fever, blood sputum and vomit which appear in infection, and has the effects of treating and killing cryptococcus neoformans and treating both principal and secondary aspect of disease; the invention has the advantages of rich medicine sources, sufficient regeneration resources, quick effect, small dosage, high cure rate, no relapse after healing, effective rate of more than 90 percent and cure rate of more than 85 percent.
Description
Technical Field
The invention relates to a compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and a preparation method thereof.
Background
The cryptococcus neoformans is one of fungi with bacteria inhalation infection in the respiratory nature, and has more types, only cryptococcus neoformans and cryptococcus gatus are human pathogenic fungi, and the cryptococcus neoformans and the cryptococcus gatus are inhaled into the lung of a human body to serve as primary focus and spread to the brain to cause meningitis, encephalitis, skin, mucous membrane and other part infections to cause chronic inflammatory diseases and abscess, patients often have intermittent headache, nausea, vomiting and low fever, have meningitis, encephalitis, brain granulation and lung infections, and have symptoms of cough, expectoration, hypodynamia, bloody sputum and the like, the cure rate is low, the recurrence rate is high, and the death rate is up to over 95%.
The existing western medicines for treating cryptococcus neoformans are too few, and only consist of western medicines such as amphotericin B, flucytosine, fluconazole and itraconazole, so that the treatment medicines have the factors of low cure rate, large side effect, more adverse reactions, high death rate and the like. At present, no medicine exists in the market, so the technical scheme has feasibility and necessity.
Disclosure of Invention
The invention aims to solve the technical problems of low cure rate, high mortality rate, great side effect, more adverse reactions and great harm to the stomach, liver and kidney caused by long-term administration of western medicines of the existing cryptococcus neoformans.
In order to solve the technical problems, the invention adopts the following technical scheme:
a compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans comprises the following components in parts by weight:
15-30 g of radix sophorae flavescentis, 15-20 g of radix stemonae, 20-25 g of radix clematidis, 15-25 g of honeysuckle, 10-15 g of spina gleditsiae, 15-20 g of coptis chinensis, 20-25 g of cowherb seed and 5-10 g of artificial musk.
The technical formula has the main functions:
the characteristic and flavor of kuh-seng, Shen nong Ben Cao Jing: bitter and cold meridians, heart meridian, liver meridian, stomach meridian, large intestine meridian and bladder meridian.
The functional indications are as follows: clear heat and dry dampness, kill parasites and induce diuresis. Can be used for treating yellow gallbladder anuresis, leucorrhea with reddish discharge, pudendal swelling, pudendal pruritus, eczema, skin pruritus, scabies, tinea, leprosy, and trichomonas vaginitis by external application.
Radix Stemonae (famous medical records) with characteristic flavor and meridian tropism: sweet, bitter and slightly damp. It enters lung meridian.
The functional indications are as follows: lung moistening lung qi for relieving cough and killing parasites. Can be used for treating cough due to chronic cough, pulmonary tuberculosis cough, and pertussis, and can be used for treating gap louse, body louse, paronychia, pruritus vulvae, and antifungal.
Radix clematidis (Chinese herbal medicine and Steel eyes) with characteristic and flavor channels: pungent, salty and warm. It enters bladder meridian.
The functional indications are as follows: dispelling pathogenic wind, removing dampness, dredging collaterals, and relieving pain, and can be used for treating rheumatalgia, numbness of limbs, spasm of muscles and tendons, difficulty in flexion and extension, and hard bone and laryngopharynx.
The property and flavor of honeysuckle flower, Bencao gang mu: sweet in taste, enters lung, heart and stomach meridians, and has the functions of clearing away heat and toxic material and resisting inflammation.
The functional indications are as follows: damp fever, heat-toxin carbuncle and ulcer, tumor, bacterial infection, measles, pneumonia, encephalitis B, epidemic encephalitis, septicemia, parotitis, carbuncle, cellulitis and furuncle.
Spina Gleditsiae (spina Gleditsiae) is good at treating the symptoms of retained fluid, pungent and warm nature and flavor.
The functional indications are as follows: detumescence and detoxification, pus discharge and disinsection, anti-inflammation, anti-allergy and anticoagulation, and has the function of guiding drugs to directly reach the focus.
The Chinese goldthread from Shen nong Ben Cao Jing (Shen nong's herbal Jing) has the following properties and tastes: bitter and cold, heart, spleen, stomach, liver, gallbladder and large intestine.
The functional indications are as follows: clearing heat, eliminating dampness, clearing pathogenic fire, removing toxic substances, emesis, dysentery, jaundice, hyperpyrexia, coma, hyperactivity of heart-fire, toothache, diabetes, and antifungal and antibacterial effects.
The nature, flavor and meridian tropism of the cowherb seed from Shen nong Ben Cao Jing: bitter, neutral, entering liver and stomach meridians.
The functional indications are as follows: promoting blood circulation, dredging collaterals, promoting lactation and relieving swelling, and can be used for treating galactostasis, amenorrhea, dysmenorrhea, carbuncle, cellulitis, swelling and pain, and introducing the medicine to directly reach the focus.
The technical science is compatible: the effect of killing cryptococcus neoformans is achieved, the effects of treating both principal and secondary aspects of disease are achieved, the cure rate is improved, and the death rate is reduced.
A preparation method of a compound traditional Chinese medicine capsule for treating and killing cryptococcus neoformans comprises the following steps:
(1) the first step is as follows: taking out 5-10 parts of artificial musk in the formula for later use;
(2) the second step is that: removing impurities from 15-30 g of radix sophorae flavescentis, 15-20 g of radix stemonae, 20-25 g of radix clematidis, 15-25 g of honeysuckle, 10-15 g of spina gleditsiae, 15-20 g of coptis chinensis and 20-25 g of cowherb seed, taking 7 medicaments in total, mixing, crushing into 4-mesh coarse powder, decocting and extracting by using a traditional Chinese medicine decocting machine, adding water which is 4 times of the total weight of the coarse powder, adding 3 times of 50% ethanol, soaking for 14 hours, heating, decocting and extracting, keeping the temperature at 80-95 ℃, decocting and extracting for 4.5 hours, and filtering to remove residues to obtain liquid medicine;
(3) the third step: concentrating the liquid medicine obtained in the second step at 70-75 deg.C to obtain extract with relative density of 0.9-1.1, adding 95% ethanol when the temperature of the extract is reduced to 30 deg.C, the amount of ethanol is 6 times of the weight of the extract, stirring, standing for 24 hr, and collecting supernatant of the extract;
(4) the fourth step: recovering ethanol from the supernatant obtained in the third step by using an ethanol recoverer to obtain a semi-finished product;
(5) the fifth step: drying the semi-finished product obtained in the fourth step at a constant temperature of 95 ℃, keeping the moisture of the dried semi-finished product between 3 and 5 percent, adding the musk for later use in the first step, uniformly stirring, and crushing the mixture into fine powder of 800 meshes and 1000 meshes by using a micro-crusher;
(6) and a sixth step: adding 95% ethanol into the fine powder obtained in the fifth step, wherein the adding amount of the ethanol is 13% of the total weight of the Chinese medicinal powder, uniformly stirring and granulating, wherein a granulating screen is 50% of mesh, drying at the constant temperature of 95 ℃, keeping the water content between 3% and 5%, physically sterilizing after drying, and filling with No. 0 capsules, wherein the net weight of each capsule is 0.38 g, and the net weight error is not more than +/-3%.
The beneficial effect of adopting above-mentioned technical scheme is:
1. the invention can effectively kill the fungi which cause meningitis, encephalitis, pneumonia, skin and mucous membrane infection caused by cryptococcus neoformans, can treat chronic inflammation, thick swelling, cough, fever, blood sputum and vomit caused by infection, and has the effects of treating and killing cryptococcus neoformans and treating both principal and secondary aspect of disease.
2. The invention has the advantages of rich medicine sources, sufficient regeneration resources, quick effect, small dosage, high cure rate, no relapse after healing, effective rate of more than 90 percent and cure rate of more than 85 percent.
Detailed Description
Example 1:
a compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans comprises the following components in parts by weight:
15 g of lightyellow sophora root, 10 g of sessile stemona root, 18 g of clematis root, 21 g of honeysuckle flower, 9 g of Chinese honeylocust spine, 17 g of coptis root, 15 g of cowherb seed and 4 g of artificial musk.
Example 2:
a compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans comprises the following components in parts by weight:
18 g of lightyellow sophora root, 12 g of sessile stemona root, 15 g of clematis root, 15 g of honeysuckle flower, 13 g of Chinese honeylocust spine, 11 g of coptis root, 12 g of cowherb seed and 8 g of artificial musk.
Example 3:
a compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans comprises the following components in parts by weight:
23 g of lightyellow sophora root, 18 g of sessile stemona root, 23 g of clematis root, 21 g of honeysuckle flower, 15 g of Chinese honeylocust spine, 18 g of coptis root, 14 g of cowherb seed and 9 g of artificial musk.
Example 4:
a compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans comprises the following components in parts by weight:
18 g of lightyellow sophora root, 17 g of sessile stemona root, 17 g of golden thread, 22 g of cowherb seed, 17 g of honeysuckle flower, 11 g of Chinese honeylocust spine, 22 g of cowherb seed and 8 g of artificial musk.
The finished product produced according to the proportion and the production process flow is taken according to the dosage, has the advantages of quickly achieving the purpose of treating and killing brain, lung, skin, mucous membrane and other complications caused by cryptococcus neoformans infection, achieving the purpose of treating both symptoms and root causes without relapse, and having the taking method: the medicine is taken three times a day, two granules each time, before meals, the medicine is taken with wet boiled water, 30 days is a treatment course, the medicine is cured in 5-7 treatment courses, and the medicine is contraindicated during the taking period: smoking and wine.
A preparation method of a refreshing herbal medicine capsule for treating and killing cryptococcus neoformans comprises the following steps:
(1) the first step is as follows: taking out 5-10 g of artificial musk in the formula for later use;
(2) the second step is that: after removing impurities and mildewing and being damaged by worms, mixing and crushing 7 medicaments, namely 15-30 g of bitter sanx, 15-20 g of radix stemonae, 20-24 g of radix clematidis, 15-25 g of honeysuckle, 10-150 g of spina gleditsiae, 15-20 g of coptis chinensis and 20-25 g of cowherb seed, decocting and extracting by using a traditional Chinese medicine decocting and extracting machine, wherein the water amount of the decoction is 4 times of the total weight of the crushed coarse powder, then adding 3 times of 50% ethanol, soaking for 14 hours, then heating and decocting, keeping the boiling and extracting temperature at 80-95 ℃, decocting and extracting for 4.5 hours, and filtering and removing residues to obtain liquid medicine;
(3) the third step: concentrating the liquid medicine obtained in the second step at 70-75 deg.C to obtain extract with relative density of 0.9-1.1, adding 95% ethanol when the temperature of the extract is reduced to 30, stirring uniformly for 24 hr, and collecting supernatant of the extract;
(4) the fourth step: recovering ethanol from the supernatant obtained in the third step by using an ethanol recoverer to obtain a semi-finished product;
(5) the fifth step: drying the semi-finished product obtained in the fourth step at a constant temperature of 95%, keeping the moisture of the dried semi-finished product between 3 and 5%, adding the musk for later use in the first step, uniformly stirring, and crushing to 800-sand-containing 1000-mesh fine powder by using a micronizer;
(6) and a sixth step: adding 95% ethanol into the fine powder obtained in the fifth step, wherein the adding amount of the ethanol is 13% of the total weight of the fine powder, uniformly stirring, granulating, sieving with a 50-mesh granulating screen, drying at the constant temperature of 95 ℃, keeping the water content between 3 and 5%, physically sterilizing after drying, and filling with 0# capsules, wherein the net weight of each capsule is 0.38 g, and the net weight error is not more than +/-3%.
Typical cases
Example 1: some Deng, male, 37 years old, Guangdong province, the northern area of Zhuhai city, Guangdong province, 6 months and 18 days in 2018 diagnose cryptococcus infection pneumonia, cough, low fever, white sputum, chest pain and pleural effusion, the condition is slightly improved by intravenous drip with amphotericin B from 0.5 mg to 2 months and 1.5 mm, but blood urea and blood creatinine obviously increase, the side effect on liver and kidney functions is large, amphotericin is stopped for use, the product is used reversely for 7 days, the clinical symptoms are obviously changed, and the negative tracking of the cryptococcus neoformans is detected after 5 months of taking for 1 year and 4 months without relapse.
Example 2: certain populus in a female, 49 years old, in the northern arch area of Zhuhai city in Guangdong province, has cryptococcus neoformans pneumonia for 4 months, is often accompanied by low temperature, sometimes has high fever, coughs and vomits purulent sputum, sometimes has bloody sputum and abdominal distension, the fluconazole tablets are taken for 15 days, the symptoms are relieved after 3 days because of the aggravation of nausea and vomiting, diarrhea and abnormal liver energy are detected after the medicine capsule is taken for 3.5 months, and no relapse occurs after 8 months.
Example 3: some woman in 54 years old, in the area of gold bay in the Zhuhai city of Guangdong province, has cryptococcus meningitis, dizziness and headache, is continuous, can cause nausea and vomiting, discomfort of the whole body and indefinite spirit, has serious side effects due to fear of antifungal western medicines, obviously improves the symptoms after 10 days of taking the Chinese herbal medicine capsule, continuously takes the capsule for 6 months, detects cryptococcus negativity, and tracks the rebound in the 4 th month.
Example 4: when a certain plum is in a gulf section of the Zhuhai city of Guangdong province, a woman is 40 years old, the woman is suffering from cryptococcus pneumonia for 3 months, and the patient is often accompanied with mild cough, a small amount of mucus phlegm, general weakness, weight loss and moderate fever of 38-39 ℃ in time, the symptom is changed after taking the Chinese herbal medicine capsule for 6 days, the cryptococcus is detected to be negative after 3.5 months, and relapse is not seen after 4 months of medicine withdrawal.
Example 5: in the northarch area of Zhuhai city in Guangdong province, a certain Tang woman is 47 years old, and patients with cryptococcus neoformans suffer from cough and night sweat in 5 months (patients with AIDS in the onset period) and have the moderate temperature of 38.5 ℃, the symptoms are improved after taking the product for 10 days, the cryptococcus is detected to be negative after taking the product for 6 months, and no relapse occurs in april of a year.
Example 6: a certain woman, 61 years old, gulf baby district of Guangdong Zhuhai city, suffer from cryptococcus neoformans encephalitis 2 months to detect and determine, and the time accompanies dizziness and headache, is continuous, and sometimes has nausea and vomiting, aggravates when catching a cold, chest distress, debilitation, and the symptom is gradually relieved after taking the product for 8 days, and the negative of cryptococcus neoformans is detected after taking the product for 5 months.
Example 7: certain Zhao, female, 45 years old, Haerbin, Heilongjiang, AIDS patients with cryptococcus pneumonia, fever, cough, hyperhidrosis (sweating on exertion) and slight abdominal swelling, cough and asthma, poor diet, obvious alleviation of symptoms after taking the product for 6 days, negative detection of cryptococcus neogenesis after 6 months of continuous taking, and no relapse until 10 months of rehabilitation.
Example 8: when a male with ginger is in the age of 58, and an AIDS patient suffers from cryptococcus encephalitis for 2 months, low fever is often accompanied, dizziness and pain are continuous, vomiting, fatigue and low immunity are occasionally caused, because western medicine anti-virus drugs are taken, dreaminess is accompanied by fright, emaciation and dizziness, the patient is unconscious and deep throughout the day, the symptoms are gradually relieved after taking the product for 12 days, cryptococcus is detected to be normal after taking the product for 7 months, and no relapse is caused after 9 months of drug withdrawal.
Example 9: certain Qin, male, 47 years old, Haerbin, Heilongjiang, suffers from cryptococcus neoformans for 1.5 months, because the patient suffers from emphysema for 5 years in the early stage, the treatment symptoms are aggravated, dyspnea is aggravated, if the patient moves, the heat is often 37.5-38.5 ℃, cough and asthma, hypodynamia, slight odor stimulation, nausea and vomiting are caused, various symptoms are relieved after the patient takes the product for 10 days, the medicine is stopped after the patient continues to take the product for 7 months, the cryptococcus is negative, and the patient does not relapse in 18 months.
Example 10: a certain Liu is male, is 53 years old, is in Haerbin city of Heilongjiang, and is used for a patient in an HIV onset stage, the cough and the sweating are aggravated for one month, cryptococcus complication pneumonia is detected, mycobacterium tuberculosis negative is detected, pulmonary tuberculosis is eliminated, cough and asthma treatment is ineffective, aggravation conditions are also detected, cryptococcus positive confirmation is detected, the effect is poor when the cryptococcus positive confirmation is detected by using a common antifungal medicament, symptoms are obviously improved after the cryptococcus is detected after the cryptococcus is continuously taken for 6 months, the cryptococcus negative is detected after the cryptococcus is continuously taken for 6 months, and the patient does not relapse in two years.
Example 11: certain Yuan, female, 62 years old, Guizhou province, following the city, Heilongjiang Harbin city, patients with neonatal cryptococcus pneumonia, severe pneumonia in SARS, with femoral head necrosis, persistent dizziness and pain, nausea, vomiting, chest distress, asthenia, aggravation of common cold, dyspnea, examining cryptococcus encephalitis, and poor curative effect by using conventional antifungal drugs, symptoms are improved after taking the product for 15 days, and cryptococcus negative is detected after taking the product for 4 months. However, the clinical symptoms are not ideal, and the reason is related to a large amount of hormones in the early pneumonia and remains to be explored.
Example 12: certain mulberry, male, 43 years old, Sinkiang Wulu wood, HIV onset patients, before hospitalization, aggravated cough, ineffective common treatment for diminishing inflammation and relieving cough, hyperhidrosis, night sweat and dyspnea particularly appear at night, poor clinical treatment effect, Mycobacterium tuberculosis infection is eliminated by detection, cryptococcus negative confirmation is detected, symptoms are improved after the product is taken for 7 days, cryptococcus negative is detected after the product is taken for 3 months, HIV virus load of the patients is high, CD4 lymphocyte 40/ul immune breakdown, and the patients in the example cannot be tracked.
Example 13: certain Qianzhi, male, 59 years old, Xinjiang Wulu wood, HIV onset patients, admission to hospital for cough with excessive phlegm, heat, hyperhidrosis and dyspnea, detection of tuberculosis mycobacterium excluding structural infection, detection of cryptococcus positive confirmation, poor treatment effect by conventional antifungal drugs, and impairment of liver and kidney functions. After the product is taken for 9 days, symptoms are improved, and the cryptococcus negative withdrawal is detected after the product is taken for 5 months until 9 months do not relapse.
Example 14: certain woman in 61 years old, Sinkiang Urugiao, cryptococcus meningitis is often accompanied with dizziness and pain, continuous and continuous, weather change, aggravation of cold, occasional nausea, vomiting, hypodynamia and poor mental status, the treatment effect is not obvious after the treatment of dripping with antifungal medicines and orally taking antifungal medicines, the symptoms are obviously improved after the medicine is taken for 13 days, the cryptococcus is detected to be negative after the medicine is continuously taken for 5.5 months, all clinical symptoms are normal, and the cryptococcus is not relapsed in 14 months.
Example 15: a certain Liu is male, is 48 years old, is in Taiyuan city in Shanxi province, and has complications of cryptococcus neoformans meningitis in the disease period of HIV patients, dizziness and headache are continuous, nausea and vomiting are frequent, cold is aggravated, chest distress and hypodynamia are frequent. After the product is taken for 3 days, the symptoms are relieved, dizziness and headache are improved after the product is taken for a week, and the negative of cryptococcus neoformans is detected after the product is continuously taken for 6 months.
Example 16: the disease is characterized in that a patient with certain Tang Dynasty, a male with age of 53 years, Xinjiang Wulu wood Qi City, AIDS patients are infected with cryptococcus neoformans with complications, the patient takes antiviral western medicines for 3 years, liver function is abnormal, dizziness and headache are caused, cold symptoms are aggravated, dizziness and headache are relieved after the patient takes the medicine for 5 days, the negative of the cryptococcus neoformans is detected after the patient takes the medicine for 8 months, and the negative of the cryptococcus neoformans is detected again after the patient stops taking.
Example 17: a certain Liu is male, is 61 years old, is in the east city of Beijing city, and is used for AIDS patients, the antiviral medicine is taken for 2 years, the patients are accompanied with dizziness and headache, nausea and vomiting are caused, the dizziness and headache caused by slight cold are severe, the new cryptococcus is detected to be positive, the symptoms are relieved after the patients take the medicine for 3 days, the new cryptococcus is detected to be negative after the patients continuously take the medicine for 7 months, and the new cryptococcus is detected to be negative after the patients stop taking the medicine for 9 months.
Example 18: the disease is characterized in that a certain plum is male, 40 years old, Guiyang city, Guizhou province, acute meningitis sequelae are suffered, dizziness and headache are aggravated for 1 year, the detection of cryptococcus neoformans is positive, the symptom is relieved after the plum is taken for 8 days, the negative of cryptococcus neoformans is rechecked after the plum is continuously taken for 8 months, and the negative of cryptococcus neoformans is rechecked after the plum is taken for half a year.
Example 19: certain Luo, female, 43 years old, Guizhou province water-study county, frequent dizziness and headache, pain easing in Western medicine taking and hypnotic medicine taking symptoms are not changed, symptoms are relieved after the product is taken for 3 days, cryptococcus neoformans is detected to be positive, cryptococcus neoformans is detected to be negative after the product is taken for 5 months, and cryptococcus neoformans is detected to be negative again after the product is taken for 8 months.
Example 20: a certain Wangzao, male, 43 years old, Guizhou province, prefecture county Mazhizhen, meningitis sequela, cryptococcus neoformans infection, dizziness and headache, low fever, chest distress, hypodynamia, cold aggravation, positive cryptococcus neoformans detection, symptom relief after taking the product for 2 days, and negative cryptococcus neoformans detection after taking the product continuously for 7 months. After two years, the test is carried out again without abnormality.
Claims (2)
1. A compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans is characterized in that: the weight ratio is as follows:
15-30 g of radix sophorae flavescentis, 15-20 g of radix stemonae, 20-25 g of radix clematidis, 15-25 g of honeysuckle, 10-15 g of spina gleditsiae, 15-20 g of coptis chinensis, 20-25 g of cowherb seed and 5-10 g of artificial musk.
2. A preparation method of a compound traditional Chinese medicine capsule for treating and killing cryptococcus neoformans is characterized in that: the method comprises the following steps:
(1) the first step is as follows: taking out 5-10 parts of artificial musk in the formula for later use;
(2) the second step is that: removing impurities from 15-30 g of radix sophorae flavescentis, 15-20 g of radix stemonae, 20-25 g of radix clematidis, 15-25 g of honeysuckle, 10-15 g of spina gleditsiae, 15-20 g of coptis chinensis and 20-25 g of cowherb seed, taking 7 medicaments in total, mixing, crushing into 4-mesh coarse powder, decocting and extracting by using a traditional Chinese medicine decocting machine, adding water which is 4 times of the total weight of the coarse powder, adding 3 times of 50% ethanol, soaking for 14 hours, heating, decocting and extracting, keeping the temperature at 80-95 ℃, decocting and extracting for 4.5 hours, and filtering to remove residues to obtain liquid medicine;
(3) the third step: concentrating the liquid medicine obtained in the second step at 70-75 deg.C to obtain extract with relative density of 0.9-1.1, adding 95% ethanol when the temperature of the extract is reduced to 30 deg.C, the amount of ethanol is 6 times of the weight of the extract, stirring, standing for 24 hr, and collecting supernatant of the extract;
(4) the fourth step: recovering ethanol from the supernatant obtained in the third step by using an ethanol recoverer to obtain a semi-finished product;
(5) the fifth step: drying the semi-finished product obtained in the fourth step at a constant temperature of 95 ℃, keeping the moisture of the dried semi-finished product between 3 and 5 percent, adding the musk for later use in the first step, uniformly stirring, and crushing the mixture into fine powder of 800 meshes and 1000 meshes by using a micro-crusher;
(6) and a sixth step: adding 95% ethanol into the fine powder obtained in the fifth step, wherein the adding amount of the ethanol is 13% of the total weight of the Chinese medicinal powder, uniformly stirring and granulating, wherein a granulating screen is 50% of mesh, drying at the constant temperature of 95 ℃, keeping the water content between 3% and 5%, physically sterilizing after drying, and filling with No. 0 capsules, wherein the net weight of each capsule is 0.38 g, and the net weight error is not more than +/-3%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011169664.2A CN112138113A (en) | 2020-10-28 | 2020-10-28 | Compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011169664.2A CN112138113A (en) | 2020-10-28 | 2020-10-28 | Compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112138113A true CN112138113A (en) | 2020-12-29 |
Family
ID=73953457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011169664.2A Pending CN112138113A (en) | 2020-10-28 | 2020-10-28 | Compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112138113A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718282A (en) * | 2019-03-13 | 2019-05-07 | 贵州克艾康医药开发有限公司 | It is a kind of to treat diabetes compound Chinese herb capsule and preparation method |
-
2020
- 2020-10-28 CN CN202011169664.2A patent/CN112138113A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109718282A (en) * | 2019-03-13 | 2019-05-07 | 贵州克艾康医药开发有限公司 | It is a kind of to treat diabetes compound Chinese herb capsule and preparation method |
Non-Patent Citations (3)
| Title |
|---|
| 况卫丰等: ""中药参芪合剂辅助治疗隐球菌性脑膜炎临床研究"", 《江西医药》 * |
| 张华山: "《中医学秘里求真》", 30 November 2011, 中医古籍出版社 * |
| 王宪龄: "《中医方药学》", 31 July 2006, 人民军医出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104435764A (en) | Traditional Chinese medicine composition for treating diabetes and preparation process thereof | |
| CN112138113A (en) | Compound Chinese herbal medicine capsule for treating and killing cryptococcus neoformans and preparation method thereof | |
| CN107998256A (en) | Treat sustained release tablets of gastritis and preparation method thereof | |
| CN106138932A (en) | For treating the Chinese medicine of infantile asthma | |
| CN101693077B (en) | Medicament for treating febrile bronchial asthma and chronic bronchitis | |
| CN104623217A (en) | Traditional Chinese medicine preparation for treating asthma and preparation method thereof | |
| CN110946950A (en) | A Chinese medicinal composition for treating senile vascular dementia, and its preparation method | |
| CN101496835A (en) | Antipyretic medicament for treating common cold of children and preparation method thereof | |
| CN103977243B (en) | A kind of medicine for treating uremia refractory pruritus and preparation method thereof | |
| CN104474292B (en) | A kind of pharmaceutical composition for preventing and treating influenza and preparation method thereof | |
| CN113304218B (en) | Traditional Chinese medicine for treating feline calicivirus infection | |
| CN107184518A (en) | A kind of toothpaste alleviated or mitigate acute/chronic pharyngitis and preparation method thereof | |
| CN105381346A (en) | Traditional Chinese medicine for treating proteinuria | |
| CN104784567B (en) | A kind of pharmaceutical composition for the treatment of urinary system infection | |
| CN105920208A (en) | Medicinal composition for treating infantile wind-heat type common cold | |
| CN105194429A (en) | Traditional Chinese medicine for treating bronchial asthma | |
| CN105055687A (en) | Medicine for treating appendicitis and preparing method | |
| CN102145110B (en) | Oral medicine composition for clinically nursing high fever caused by infantile respiratory tract infection and preparation method of oral medicine composition | |
| CN104257956A (en) | Traditional Chinese medicine composition with effects of relieving cough and asthma | |
| CN104740162A (en) | Drug for treating streptococcus pneumonia syndrome of phlegm-heat obstructing lung and preparation method for drug | |
| CN117100829A (en) | Traditional Chinese medicine preparation for treating novel coronavirus infection and preparation method thereof | |
| CN110170021A (en) | A kind of compound butterfly grass extract and preparation method thereof for preventing and treating asthma | |
| CN115814030A (en) | Traditional Chinese medicine composition for preventing and treating new coronavirus and application thereof | |
| CN114588233A (en) | Composition for treating acute gout | |
| CN115607644A (en) | Traditional Chinese medicine composition for treating IgA nephropathy and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20201229 |
|
| WD01 | Invention patent application deemed withdrawn after publication |